Letter

NICE transparency

Let cost effectiveness models be open to scrutiny

BMJ 2007; 335 doi: 10.1136/bmj.39360.379664.BE (Published 11 October 2007)
Cite this as: BMJ 2007;335:735.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Chris Poole, director1,
  2. Samir Agrawal, consultant haematologist2,
  3. Craig J Currie, honorary senior research fellow3
  1. 1Pharmatelligence LLP, Cardiff MediCentre, Cardiff
  2. 2Department of Haematological Oncology, St Bartholomew's Hospital, London
  3. 3Department of Medicine, Cardiff University, Cardiff
  1. drchrispoole@googlemail.com

    In light of the recent ruling over the National Institute for Health and Clinical Excellence's (NICE) decision on donezepil,1 2 we wish to comment on the adversarial system of drug evaluation and the inadequacy of NICE providing read-only versions of cost effectiveness models for the purposes of reviewing their decisions.

    The assertion that “[NICE] is not in a position to deal with the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular